1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
- Author
-
Miguel Canales, J. J. Sanchez-blanco, Carlos Montalbán, Jose Francisco Tomas, Joan Bargay, Eulogio Conde, Jose Luis Bello, Dolores Caballero, Eva Domingo-Domenech, Luis Palomera, Juan F. García, Ana Muntañola, Juan-Manuel Sancho, Javier Peñalver, Mar Garcia, Carlos Grande, Reyes Arranz, Carlos Panizo, Concepción Nicolás, Antonio Salar, and María José Rodríguez more...
- Subjects
Bendamustine ,Pathology ,medicine.medical_specialty ,business.industry ,Mucosa-Associated Lymphoid Tissue Lymphoma ,Immunology ,Phases of clinical research ,Cell Biology ,Hematology ,Long term results ,Marginal zone ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Lymphatic system ,030220 oncology & carcinogenesis ,Localized disease ,medicine ,Rituximab ,business ,030215 immunology ,medicine.drug - Abstract
To the editor: Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) present in most cases as localized disease and can be successfully treated with local therapies or antibiotics.[1][1][⇓][2][⇓][3]-[4][4] Moreover, patients with multicentric or extensive disease more...
- Published
- 2017
- Full Text
- View/download PDF